



Contact:
At The Company:
Robert McNally
404.727.0971 or rmcnally@geovax.com

At Financial Relations Board:
Leslie Loyet
Investor Relations
312.640.6672 or lloyet@mww.com

Nikki Snodgrass
Media Relations
312.640.6732 or nsnodgrass@mww.com

**FOR IMMEDIATE RELEASE
WEDNESDAY, AUGUST 26, 2009**

**GEOVAX TO PRESENT AT THE RODMAN & RENSHAW
11TH ANNUAL HEALTHCARE CONFERENCE**

ATLANTA – August 26, 2009 - GeoVax Labs, Inc. (OTC BB: GOVX) (the “Company”), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a company overview at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 4:30 p.m. ET at the New York Palace Hotel in New York.

To access the live webcast of the presentation, please visit the GeoVax website at <http://www.geovax.com>, or <http://www.wsw.com/webcast/rrshq15/govx.ob>. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads. An archived replay will be available on the Company’s site for 90 days following the live presentation.

Dr. McNally will present an overview of GeoVax’s vaccine technology and will report the latest progress on the Company’s Phase 2a preventative human vaccine trial and plans for its upcoming therapeutic human vaccine trials. Management also plans to meet one-on-one with current and prospective GeoVax investors, analysts and other potential Company partners.

“The Rodman Conference offers GeoVax an outstanding platform in which to share its milestone accomplishments related to our promising HIV-1/AIDS vaccines and plans for therapeutic human trials with the investment community. We remain devoted to finding a prevention and cure for AIDS while simultaneously managing our costs,” stated Dr. McNally.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., will hold its Annual Global Investment Conference from September 9-11, 2009 at the New York Palace

MORE

GeoVax Labs, Inc.

Add 1

Hotel, New York City. The Conference will feature tracks devoted to Healthcare, Metals & Mining, Energy, Cleantech, Asia, Community & Regional Banks, Growth, & Maritime. More than 500 public & private companies have already registered to present at this year's conference. Over 2,500 conference attendees are expected including institutional investors, venture capitalists, sophisticated private investors, business development/partnering executives, members of private equity firms, and other experts from the worldwide medical and research communities.

HIV/AIDS Background

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Presently, there is little to prevent HIV transmission other than education, circumcision, and condoms. It is obvious from the spread of the disease that these methods are not adequate. Existing treatments for individuals infected with HIV include anti-retroviral therapies that are effective but have serious medical side effects and are expensive (upwards of \$1,500/month). This cost is borne primarily by the individual and sometimes by third party insurance, local healthcare, federal or world health organizations. Development and distribution of an effective HIV/AIDS vaccine holds great promise. The GeoVax Vaccine would cost a fraction of the cost of current treatments and, to date, has not elicited serious adverse side effects in several human trials. A population vaccinated with an effective HIV-1 vaccine would be expected to significantly decrease the prevalence of AIDS over time.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a \$17 million IPCAVD grant awarded in late 2007.

MORE

GeoVax Labs, Inc.

Add 2

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

###